Group 1 - The article highlights the increasing presence of pension plans among the top holders of ETFs, indicating a shift in investment strategies towards equity assets [1][7] - The report details that on July 22, the Fortune China Securities Hong Kong Stock Connect Technology ETF will be listed with a total of 1.119 billion shares, and pension plans occupy 9 out of the top 11 holders [1][2] - The largest holder is the China Post Group Enterprise Pension Plan, owning 28 million shares, which is 2.5% of the total fund [1][2] Group 2 - Other notable pension plans include Shandong Province (No. 5) and Beijing (No. 1) occupational pension plans, each holding 18 million shares, representing 1.61% of the total [1][2] - The article mentions that pension plans are increasingly investing in ETFs, with 92 pension plans appearing in the top 10 holders of 79 ETFs, holding a total of 5.819 billion shares, a significant increase compared to the first half of 2024 [7] - The total investment scale of occupational pension funds in China reached 3.11 trillion yuan by the end of 2024, indicating the growing importance of these funds in the capital market [7][8] Group 3 - The article notes that regulatory encouragement for long-term capital to enter the market may lead to an increase in equity investment ratios among pension plans, as they seek higher long-term returns [8] - The implementation of long-term performance assessment guidelines for pension fund managers is expected to alleviate short-term performance pressures, allowing for more strategic investment approaches [8]

【导读】年金计划"组团"现身ETF前十大持有人名单 中国基金报记者 吴君 例如，今年4月上市交易的工银瑞信国证港股通创新药ETF的前十大持有人名单中也出现了多 只年金计划，其中，国家能源投资集团企业年金计划持有5000.72万份，占场内基金总份额 的3.95%，排名首位；农行、建行、交行、工行等几大国有银行的企业年金计划也配置了该 基金，如中国农业银行企业年金计划持有4800.67万份，中国建设银行企业年金计划持有 4650.29万份；中国华能集团企业年金计划持有3334.49万份。此外，河北、广东、江苏等地 的职业年金计划也持有该基金。 | 序号 | 持有人名称(全称) | 持有基金份额(份) | 占场内基金 | | --- | --- | --- | --- | | | | | 总份额的比例(%) | | | 国家能源投资集团有限责任 | | | | l | 公司企业年金计划一中国建 | 50,007,166.00 | 3.95 | | | 设银行股份有限公司 | | | | | 工银瑞信基金公司一农行一 | | | | 2 | 中国农业银行离退休人员福 | 50,003,166.00 | 3.95 | ...

Institutional Movements - Long-term funds are continuously increasing their investments in the innovative drug sector amid recent market adjustments, indicating a long-term value in this sector, although a focus on quality companies is necessary due to previous strong price increases [1] Long-term Funds Entering via ETFs - Several newly launched innovative drug-themed ETFs have seen significant purchases from long-term funds this year, with Barclays Bank being a major holder of multiple ETFs, holding 20 million yuan in one and 85 million yuan in another [2] - Corporate pension plans have also heavily invested in innovative drug ETFs, with several plans holding over 40 million yuan each [2] - As of July 3, the Huatai-PineBridge Hang Seng Innovative Drug ETF has increased by over 60% since its launch, while the ICBC Credit Suisse National Index Hong Kong Innovative Drug ETF has risen nearly 30% [2] Fund Flows - The innovative drug-themed ETFs have attracted substantial net subscriptions, totaling nearly 9 billion yuan since June, with specific ETFs like the Huatai-PineBridge and GF Hong Kong Innovative Drug ETFs seeing net subscriptions of 4.44 billion yuan and 2.305 billion yuan, respectively [3] New Fund Launches - Public funds are increasing their focus on innovative drug-themed funds, with several new funds currently being issued, including the Xinyuan CSI Hong Kong Innovative Drug Index Fund and others set to launch soon [4] Long-term Outlook for the Innovative Drug Industry - The innovative drug sector in China is expected to continue its long-term positive trend, with significant overseas collaborations and clinical advancements being recognized by multinational pharmaceutical companies [5] - The recent rise in the innovative drug sector is attributed to a decade of accumulated competitive advantages rather than short-term market fluctuations, suggesting ongoing investment opportunities in quality innovative drug companies [5] - The industry is likely to experience linear development, while market performance may be more volatile, necessitating a focus on fundamental research and selective investment strategies [5]

Core Viewpoint - Barclays Bank has significantly increased its investment in Hong Kong innovative pharmaceuticals through ETFs, indicating a strong belief in the sector's growth potential [1][2][4]. Group 1: Investment Details - As of June 30, Barclays Bank held 20 million shares of the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Select ETF, accounting for 4.5997% of the total fund shares, making it the largest shareholder [3]. - Previously, Barclays held 85 million shares of the Huatai-PineBridge Hang Seng Innovative Drug ETF, representing 42.02% of the total shares, and achieved a return of over 56% since the fund's inception [4][5]. Group 2: Market Performance - The innovative drug sector has seen a remarkable rebound since the end of 2024, with the Hang Seng Innovative Drug Index rising nearly 68% year-to-date as of July 2 [8]. - Recent favorable policies from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, proposing 16 measures to enhance R&D support and improve market access [8]. Group 3: Market Sentiment and Future Outlook - Current market adjustments in the innovative drug sector are attributed to a combination of market sentiment and capital flow, with institutional holdings remaining at historical average levels [9]. - Analysts believe that the Chinese innovative drug industry is at a critical turning point, with a focus on ADC and dual-antibody technologies expected to capture significant market share in global immunotherapy [9][10].

Group 1 - Barclays Bank is the largest holder of the newly listed Hong Kong innovative drug ETF, holding 20 million shares, which accounts for 4.5997% of the total fund shares [2][3] - The innovative drug sector has seen a significant rebound since the end of 2024, with the Hang Seng Innovative Drug Index rising nearly 68% year-to-date as of July 2 [7] - The recent policy measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, proposing 16 measures to enhance R&D support and improve market accessibility [7][8] Group 2 - In the past, Barclays also held a significant position in the Huatai-PineBridge Hang Seng Innovative Drug ETF, owning 85 million shares, which represented 42.02% of the total shares, with a return of over 56% since its inception [4][2] - Recent trends show that the top holders of other innovative drug ETFs are primarily brokerages, private equity, individual investors, and corporate pension plans, indicating a diverse investor base [5] - The innovative drug industry in China is at a critical turning point, with a focus on ADC and dual-antibody technologies, which are expected to capture significant market share in global immunotherapy [8]

Core Viewpoint - Barclays Bank has become the largest holder of two Hong Kong-listed innovative drug ETFs, indicating a strategic investment in the innovative drug sector in Hong Kong [2][3]. Group 1: Investment Activity - As of June 30, Barclays Bank held 20 million shares of the Hua Bao Hang Seng Hong Kong Stock Connect Innovative Drug Select ETF, accounting for 4.5997% of the total fund shares, making it the largest holder [4]. - Previously, Barclays held 85 million shares of the Huatai-PineBridge Hang Seng Innovative Drug ETF (QDII) at the end of 2024, representing 42.02% of the total shares, also ranking as the largest holder [6][7]. Group 2: Market Performance - The innovative drug sector has seen a significant rebound since the end of 2024, with a notable increase over the past six months [5]. - As of July 2, the Hang Seng Innovative Drug Index has risen nearly 68% year-to-date, reflecting strong market performance [10]. Group 3: Policy Support - Recent favorable policies from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, proposing 16 measures to enhance R&D support, inclusion in insurance directories, and improve payment capabilities [10]. - Analysts believe that these policies demonstrate the government's commitment to fostering a high-quality development environment for innovative drugs, which could expand market opportunities [10]. Group 4: Future Outlook - The innovative drug industry in China may be at a critical turning point, with ADC and dual-antibody technologies expected to capture significant market share in global immunotherapy [11]. - Investment focus is shifting towards second-generation immuno-oncology drugs, metabolic diseases, and companies with strong clinical data and international capabilities [11].